Cybin (TSE:CYBN) has released an update.
Cybin Inc. has reported promising results from its Phase 2 study of CYB003, showing significant long-term efficacy in treating major depressive disorder with 100% of participants responding to treatment and 71% achieving remission after 12 months. The study highlights CYB003’s robust and durable effects, showing a 23-point reduction in depression scores and a strong safety profile.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.